查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
宠物用医药品的全球市场 (2019-2029年):各动物、给药途径、产品、地区的市场规模、占有率、趋势分析、机会、预测
市场调查报告书
商品编码
1274839

宠物用医药品的全球市场 (2019-2029年):各动物、给药途径、产品、地区的市场规模、占有率、趋势分析、机会、预测

Companion Animal Pharmaceuticals Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Animal ; By Route of Administration ; By Product ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球宠物用医药品的市场规模，从2022年的348亿美元，在预测期间中预计以4.42％的年复合成长率发展，2029年成长到451亿2,000万美元的规模。

市场主要的促进成长因素，是宠物的饲养数增加，宠物疾病的盛行率上升，对宠物健康的重要性的认识高涨等。还有针对动物健康的支出增加伴随的宠物保险需求的剧增，动物医疗保健相关R&D投资增加，全球宠物饲养率高等，也预期更加牵引在预测期间内的市场。

本报告提供全球宠物用医药品的市场调查，市场概要，市场成长的各种影响因素分析，技术趋势，法律制度，市场规模的变化、预测，各种区分、各地区/主要国家的明细，竞争环境，主要企业简介等彙整资讯。

目录

第1章 调查架构

第2章 摘要整理

第3章 全球宠物用医药品市场相关洞察

  • 产业的价值链分析
  • DROC分析
    • 促进因素
    • 阻碍因素
    • 机会
    • 课题
  • 产品的进步/最近的开发
  • 法律规范
  • 波特的五力分析

第4章 全球宠物用医药品市场:概要

  • 市场规模、预测
  • 市场占有率、预测
    • 各动物
      • 狗
      • 猫
      • 马
      • 其他
    • 各给药途径
      • 口服
      • 注射
      • 局部
    • 各产品
      • 抗生素
      • 抗发炎药
      • 寄生虫驱除剂
      • 疫苗
      • 其他
    • 各地区
      • 北美
      • 欧洲
      • 亚太地区
      • 南美
      • 中东、非洲

第5章 北美的宠物用医药品市场

  • 市场规模、预测
  • 市场占有率、预测
    • 各动物
    • 各给药途径
    • 各产品
    • 各国

第6章 欧洲的宠物用医药品市场

  • 市场规模、预测
  • 市场占有率、预测
    • 各动物
    • 各给药途径
    • 各产品
    • 各国

第7章 亚太地区的宠物用医药品市场

  • 市场规模、预测
  • 市场占有率、预测
    • 各动物
    • 各给药途径
    • 各产品
    • 各国

第8章 南美的宠物用医药品市场

  • 市场规模、预测
  • 市场占有率、预测
    • 各动物
    • 各给药途径
    • 各产品
    • 各国

第9章 中东、非洲的宠物用医药品市场

  • 市场规模、预测
  • 市场占有率、预测
    • 各动物
    • 各给药途径
    • 各产品
    • 各国

第10章 竞争情形

  • 主要企业、产品清单
  • 市场占有率分析
  • 竞争基准:各经营参数
  • 主要的策略性展开 (M&A、联盟等)

第11章 COVID-19对全球宠物用医药品市场的影响

第12章 企业简介 (企业概要、财务矩阵、竞争情形、主要人力资源、主要的竞争对手、联络处、策略性展望、SWOT分析)

  • Zoetis Inc.
  • Merck Animal Health
  • Boehringer Ingelheim International GmbH
  • Elanco Animal Health Incorporated
  • Bayer AG
  • Virbac
  • Dechra Pharmaceuticals PLC
  • Vetoquinol SA
  • Ceva Sante Animale
  • Kindred Biosciences, Inc.
  • Norbrook
  • IDEXX Laboratories, Inc.
  • Animalcare Group plc
  • Neogen Corporation
  • Heska Corporation
  • 其他的主要企业

第13章 主要策略性建议

第14章 调查手法

简介目录
Product Code: BWC23375

Global Companion Animal Pharmaceuticals Market Size Set to Touch USD 45.12 Billion by 2029.

Global companion animal pharmaceuticals market is flourishing because of an increasing awareness about animal health and wellness, rising pet ownership, increasing humanization of pets, and growing adoption of technology advancements in veterinary healthcare.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global companion animal pharmaceuticals market size at USD 34.8 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global companion animal pharmaceuticals market size to grow at a CAGR of 4.42% reaching a value of USD 45.12 billion by 2029. Major growth drivers for the global companion animal pharmaceuticals market include an increasing number of pet adoptions, the rising prevalence of pet diseases, and the growing awareness of the importance of pet health. Also, a surge in demand for pet insurance owing to the rising expenditure on animal health, escalating investments in R&D for animal healthcare, and high rates of pet ownership across the globe are expected to further drive the global market during the period in analysis. However, stringent regulations and lengthy approval processes for animal pharmaceuticals and high costs associated with veterinary drugs and treatments are anticipated to hinder the global market during the forecast period.

Global Companion Animal Pharmaceuticals Market - Overview:

A companion animal differs from an assistive animal in that it does not receive any specific training to help a person with a disability. Instead, companion animals provide humans with companionship, entertainment, emotional support, and other functions that humans need from animals. Veterinarians who specialize in companion animals can perform a range of medical services, including treating injuries and illnesses, performing surgeries, administering vaccines, and prescribing medications. They are also responsible for euthanizing animals when necessary. The owners of companion animals are responsible for the animal's well-being, actions, and care. When choosing a companion animal, it is essential to consider the owner's lifestyle, budget, and ability to provide proper care throughout the animal's life. Animal health products, such as feeds, are the most commonly used products for animal healthcare, and this market includes pharmaceuticals and vaccines that improve the health and welfare of animals. Animals obtain nutrition from these products. In recent years, the number of people who own and spend money on companion animals has increased, and pet owners now spend more money per pet than in the past. Pet owners prioritize their pet's health and wellness and expect them to live a healthy life.

Impact of COVID-19 on Global Companion Animal Pharmaceuticals Market

COVID-19 pandemic had a dual impact on the global companion animal pharmaceuticals market. On the positive side, with lockdowns and social distancing measures in place, people were spending more time at home and turning to pets for comfort and companionship. It led to an increase in pet ownership and a surge in demand for animal healthcare products and services, including pharmaceuticals. However, on the negative side, the pandemic disrupted global supply chains and manufacturing activities, causing shortages of raw materials and finished products. It led to production delays and increased prices, which affected the profitability of the market players. Moreover, with the focus on human healthcare during the pandemic, veterinary care and services were deprioritized in some regions, leading to a decline in demand for companion animal pharmaceuticals. Despite these challenges, the overall impact of the pandemic on the companion animal pharmaceuticals market was relatively moderate, and the market is expected to recover as the situation normalizes. As people continue to value the companionship of their pets, the demand for animal healthcare products and services is expected to remain robust in the long term.

Global Companion Animal Pharmaceuticals Market - By Animal

By animal, the global companion animal pharmaceuticals market is divided into Dogs, Cats, and Horses segments. The dogs segment held the highest share in the global companion animal pharmaceuticals market in 2022. According to Holland Insurance Company Pty. Ltd., India is experiencing an exponential growth in its pet dog population, driven by urbanization and millennials opting for dogs as pets. Also, the growing awareness of pet insurance and animal health importance is expected to boost the market growth. On the other hand, the cats' segment is projected to grow at the highest compound annual growth rate (CAGR) during the forecast period. Cats are becoming increasingly popular in certain countries like Canada and are preferred over dogs. Additionally, many companies are concentrating on expanding their product range for cats due to their greater susceptibility to diseases when compared to other pets.

Competitive Landscape:

Major players operating in the global companion animal pharmaceuticals market include: Nestle SA, The Hershey Company, Lindt & Sprungli AG, Mondelez International, Inc., Ferrero Group, Haribo GmbH & Co. KG, Perfetti Van Melle, Russell Stover Chocolates, Wrigley Jr. Company, Ricola AG, Chupa Chups SA, Jelly Belly Candy Company, Lotte Group, Swizzels Matlow Limited, and The Topps Company. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the Global Companion Animal Pharmaceuticals Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Companion Animal Pharmaceuticals Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Companion Animal Pharmaceuticals Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Growing pet ownership and increasing humanization of pets
      • 3.2.1.2. Rising awareness about animal health and wellness
      • 3.2.1.3. Advancements in veterinary healthcare technology
    • 3.2.2. Restraints
      • 3.2.2.1. Stringent regulations and lengthy approval processes for animal pharmaceuticals
      • 3.2.2.2. High costs associated with veterinary drugs and treatments
    • 3.2.3. Opportunities
      • 3.2.3.1. Increasing demand for personalized and customized medicine for pets
      • 3.2.3.2. Rising trend of pet insurance, providing financial assistance for pet healthcare
    • 3.2.4. Challenges
      • 3.2.4.1. Concerns over the safety and efficacy of animal pharmaceuticals
      • 3.2.4.2. Lack of awareness and education about pet healthcare in certain regions
  • 3.3. Product Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Companion Animal Pharmaceuticals Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share and Forecast
    • 4.2.1. By Animal
      • 4.2.1.1. Dogs
      • 4.2.1.2. Cats
      • 4.2.1.3. Horses
      • 4.2.1.4. Others
    • 4.2.2. By Route of Administration
      • 4.2.2.1. Oral
      • 4.2.2.2. Injectable
      • 4.2.2.3. Topical
    • 4.2.3. By Product
      • 4.2.3.1. Antibiotics
      • 4.2.3.2. Anti-inflammatory
      • 4.2.3.3. Parasiticides
      • 4.2.3.4. Vaccines
      • 4.2.3.5. Others
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia Pacific (APAC)
      • 4.2.4.4. Latin America (LATAM)
      • 4.2.4.5. Middle East and Africa (MEA)

5. North America Companion Animal Pharmaceuticals Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Animal
    • 5.2.2. By Route of Administration
    • 5.2.3. By Product
    • 5.2.4. By Country
      • 5.2.4.1. United States
      • 5.2.4.1.1. By Animal
      • 5.2.4.1.2. By Route of Administration
      • 5.2.4.1.3. By Product
      • 5.2.4.2. Canada
      • 5.2.4.2.1. By Animal
      • 5.2.4.2.2. By Route of Administration
      • 5.2.4.2.3. By Product

6. Europe Companion Animal Pharmaceuticals Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Animal
    • 6.2.2. By Route of Administration
    • 6.2.3. By Product
    • 6.2.4. By Country
      • 6.2.4.1. Germany
      • 6.2.4.1.1. By Animal
      • 6.2.4.1.2. By Route of Administration
      • 6.2.4.1.3. By Product
      • 6.2.4.2. United Kingdom
      • 6.2.4.2.1. By Animal
      • 6.2.4.2.2. By Route of Administration
      • 6.2.4.2.3. By Product
      • 6.2.4.3. Italy
      • 6.2.4.3.1. By Animal
      • 6.2.4.3.2. By Route of Administration
      • 6.2.4.3.3. By Product
      • 6.2.4.4. France
      • 6.2.4.4.1. By Animal
      • 6.2.4.4.2. By Route of Administration
      • 6.2.4.4.3. By Product
      • 6.2.4.5. Spain
      • 6.2.4.5.1. By Animal
      • 6.2.4.5.2. By Route of Administration
      • 6.2.4.5.3. By Product
      • 6.2.4.6. Belgium
      • 6.2.4.6.1. By Animal
      • 6.2.4.6.2. By Route of Administration
      • 6.2.4.6.3. By Product
      • 6.2.4.7. Russia
      • 6.2.4.7.1. By Animal
      • 6.2.4.7.2. By Route of Administration
      • 6.2.4.7.3. By Product
      • 6.2.4.8. The Netherlands
      • 6.2.4.8.1. By Animal
      • 6.2.4.8.2. By Route of Administration
      • 6.2.4.8.3. By Product
      • 6.2.4.9. Rest of Europe
      • 6.2.4.9.1. By Animal
      • 6.2.4.9.2. By Route of Administration
      • 6.2.4.9.3. By Product

7. Asia-Pacific Companion Animal Pharmaceuticals Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Animal
    • 7.2.2. By Route of Administration
    • 7.2.3. By Product
    • 7.2.4. By Country
      • 7.2.4.1. China
      • 7.2.4.1.1. By Animal
      • 7.2.4.1.2. By Route of Administration
      • 7.2.4.1.3. By Product
      • 7.2.4.2. India
      • 7.2.4.2.1. By Animal
      • 7.2.4.2.2. By Route of Administration
      • 7.2.4.2.3. By Product
      • 7.2.4.3. Japan
      • 7.2.4.3.1. By Animal
      • 7.2.4.3.2. By Route of Administration
      • 7.2.4.3.3. By Product
      • 7.2.4.4. South Korea
      • 7.2.4.4.1. By Animal
      • 7.2.4.4.2. By Route of Administration
      • 7.2.4.4.3. By Product
      • 7.2.4.5. Australia & New Zealand
      • 7.2.4.5.1. By Animal
      • 7.2.4.5.2. By Route of Administration
      • 7.2.4.5.3. By Product
      • 7.2.4.6. Indonesia
      • 7.2.4.6.1. By Animal
      • 7.2.4.6.2. By Route of Administration
      • 7.2.4.6.3. By Product
      • 7.2.4.7. Malaysia
      • 7.2.4.7.1. By Animal
      • 7.2.4.7.2. By Route of Administration
      • 7.2.4.7.3. By Product
      • 7.2.4.8. Singapore
      • 7.2.4.8.1. By Animal
      • 7.2.4.8.2. By Route of Administration
      • 7.2.4.8.3. By Product
      • 7.2.4.9. Vietnam
      • 7.2.4.9.1. By Animal
      • 7.2.4.9.2. By Route of Administration
      • 7.2.4.9.3. By Product
      • 7.2.4.10. Rest of APAC
      • 7.2.4.10.1. By Animal
      • 7.2.4.10.2. By Route of Administration
      • 7.2.4.10.3. By Product

8. Latin America Companion Animal Pharmaceuticals Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Animal
    • 8.2.2. By Route of Administration
    • 8.2.3. By Product
    • 8.2.4. By Country
      • 8.2.4.1. Brazil
      • 8.2.4.1.1. By Animal
      • 8.2.4.1.2. By Route of Administration
      • 8.2.4.1.3. By Product
      • 8.2.4.2. Mexico
      • 8.2.4.2.1. By Animal
      • 8.2.4.2.2. By Route of Administration
      • 8.2.4.2.3. By Product
      • 8.2.4.3. Argentina
      • 8.2.4.3.1. By Animal
      • 8.2.4.3.2. By Route of Administration
      • 8.2.4.3.3. By Product
      • 8.2.4.4. Peru
      • 8.2.4.4.1. By Animal
      • 8.2.4.4.2. By Route of Administration
      • 8.2.4.4.3. By Product
      • 8.2.4.5. Rest of LATAM
      • 8.2.4.5.1. By Animal
      • 8.2.4.5.2. By Route of Administration
      • 8.2.4.5.3. By Product

9. Middle East & Africa Companion Animal Pharmaceuticals Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Animal
    • 9.2.2. By Route of Administration
    • 9.2.3. By Product
    • 9.2.4. By Country
      • 9.2.4.1. Saudi Arabia
      • 9.2.4.1.1. By Animal
      • 9.2.4.1.2. By Route of Administration
      • 9.2.4.1.3. By Product
      • 9.2.4.2. UAE
      • 9.2.4.2.1. By Animal
      • 9.2.4.2.2. By Route of Administration
      • 9.2.4.2.3. By Product
      • 9.2.4.3. Qatar
      • 9.2.4.3.1. By Animal
      • 9.2.4.3.2. By Route of Administration
      • 9.2.4.3.3. By Product
      • 9.2.4.4. Kuwait
      • 9.2.4.4.1. By Animal
      • 9.2.4.4.2. By Route of Administration
      • 9.2.4.4.3. By Product
      • 9.2.4.5. South Africa
      • 9.2.4.5.1. By Animal
      • 9.2.4.5.2. By Route of Administration
      • 9.2.4.5.3. By Product
      • 9.2.4.6. Nigeria
      • 9.2.4.6.1. By Animal
      • 9.2.4.6.2. By Route of Administration
      • 9.2.4.6.3. By Product
      • 9.2.4.7. Algeria
      • 9.2.4.7.1. By Animal
      • 9.2.4.7.2. By Route of Administration
      • 9.2.4.7.3. By Product
      • 9.2.4.8. Rest of MEA
      • 9.2.4.8.1. By Animal
      • 9.2.4.8.2. By Route of Administration
      • 9.2.4.8.3. By Product

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Companion Animal Pharmaceuticals Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Companion Animal Pharmaceuticals Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Zoetis Inc.
  • 12.2. Merck Animal Health
  • 12.3. Boehringer Ingelheim International GmbH
  • 12.4. Elanco Animal Health Incorporated
  • 12.5. Bayer AG
  • 12.6. Virbac
  • 12.7. Dechra Pharmaceuticals PLC
  • 12.8. Vetoquinol SA
  • 12.9. Ceva Sante Animale
  • 12.10. Kindred Biosciences, Inc.
  • 12.11. Norbrook
  • 12.12. IDEXX Laboratories, Inc.
  • 12.13. Animalcare Group plc
  • 12.14. Neogen Corporation
  • 12.15. Heska Corporation
  • 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations